[Development of XXXX following modified 3-wall decompression of the orbita in @entity4903 for functional and rehabilitative indication].

@entity1 @entity227 @entity353 @entity1319 @entity1781 @entity892 @entity4903
INTRODUCTION: Permanent @entity227 due to an increase in volume of the orbital contents may be the result of the failure of conservative therapeutic concepts in the treatment of @entity4903 . Considerable progress has been achieved in developing successful orbital decompression techniques with regard to functional and cosmetic outcome. Decompression techniques with resection of the bony orbital walls are adequate tools in restoring visual acuity and reducing exophthalmus. A considerable degree of @entity1319 has been described in the literature depending on the techniques being used. PURPOSE: The purpose of this study was to investigate whether a modified technique of 3-wall orbital decompression with preservation of a medial part of the periorbital tissue to support the medial rectus muscle, is able to reduce the postoperative risk of @entity892 . MATERIAL AND METHODS: A modified technique of orbital 3-wall decompression with resection of the medial orbital wall, the medial orbital floor and the floor of the frontal sinus has been used in @entity1 with @entity1781 (n = 20) and for cosmetic reasons (n = 7) in cases of uni- or bilateral proptosis. Analysis of the results was performed concerning visual outcome, @entity353 and development of horizontal and vertical motility changes. RESULTS: In all cases of @entity1781 improvement of visual function at an average of 4.63 +/- 4.5 lines could be achieved. @entity353 was 3.2 +/- 2.4 mm in the functional group and 3.9 +/- 1.7 mm in the rehabilitative group. In this group motility of the medial rectus muscle remained unaffected except in one eye. In the functional group motility deterioration was observed in 62 %. CONCLUSION: The modified 3-wall decompression technique with preservation of a medial periorbital tissue strip is an adequate alternative technique in the therapy of @entity1781 and exophthalmus @entity4903 with a low risk of @entity1319 .
